Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Pharmacological Research|July 30, 2016
BRET-based β-arrestin2 recruitment to the histamine H1 receptor for investigating antihistamine binding kineticsReggie Bosma, Ryo Moritani, Rob Leurs, et al.
International Journal of Molecular Sciences|May 11, 2024
Multiplex Detection of Fluorescent Chemokine Binding to CXC Chemokine Receptors by NanoBRETJustyna M Adamska, Spyridon Leftheriotis, Reggie Bosma, et al.
European Journal of Pharmacology|September 12, 2018
The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine HReggie Bosma, Jelle van den Bor, Henry F Vischer, et al.
Frontiers in Pharmacology|October 17, 2017
The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 ReceptorReggie Bosma, Gesa Witt, Lea A I Vaas, et al.
RNA (New York, N.Y.)|November 28, 2012
Fluorescence-based alternative splicing reporters for the study of epithelial plasticity in vivoJason A Somarelli, Daneen Schaeffer, Reggie Bosma, et al.
ACS Omega|May 31, 2021
Exploring the Effect of Cyclization of Histamine H1 Receptor Antagonists on Ligand Binding KineticsZhiyong Wang, Reggie Bosma, Sebastiaan Kuhne, et al.
International Journal of Molecular Sciences|March 25, 2022
BRET-Based Biosensors to Measure Agonist Efficacies in Histamine H1 Receptor-Mediated G Protein Activation, Signaling and Interactions with GRKs and β-ArrestinsEléonore W E Verweij, Reggie Bosma, Meichun Gao, et al.
Journal of Medicinal Chemistry|September 20, 2016
Identification of Ligand Binding Hot Spots of the Histamine H1 Receptor following Structure-Based Fragment OptimizationSebastiaan Kuhne, Albert J Kooistra, Reggie Bosma, et al.
Journal of Medicinal Chemistry|December 26, 2024
Probing the Histamine H1 Receptor Binding Site to Explore Ligand Binding KineticsSebastiaan Kuhne, Reggie Bosma, Albert J Kooistra, et al.
Molecular Pharmacology|March 29, 2025
Pharmacological characterization of a clinical candidate, TG-0054, a small molecule inverse agonist targeting CXCR4Kylie S Pan, Ziming Wang, Cy Pfeil, et al.
Pageof 3